These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6794745)

  • 61. Haemostatic variables associated with diabetes and its complications.
    Fuller JH; Keen H; Jarrett RJ; Omer T; Meade TW; Chakrabarti R; North WR; Stirling Y
    Br Med J; 1979 Oct; 2(6196):964-6. PubMed ID: 509177
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes.
    Evans RJ; Lane J; Holman RR; Turner RC
    Diabetes Care; 1982; 5(4):433-7. PubMed ID: 6818012
    [TBL] [Abstract][Full Text] [Related]  

  • 63. ABC of diabetes: treatment.
    Wheeley MS
    Br Med J (Clin Res Ed); 1982 Oct; 285(6350):1278. PubMed ID: 6812843
    [No Abstract]   [Full Text] [Related]  

  • 64. Increased fibrinolytic potential induced by gliclazide in type I and type II diabetic patients.
    Gram J; Jespersen J
    Metabolism; 1992 May; 41(5 Suppl 1):25-9. PubMed ID: 1574011
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Changes in systolic time intervals during treatment of diabetes mellitus.
    Sykes CA; Wright AD; Malins JM; Pentecost BL
    Br Heart J; 1977 Mar; 39(3):255-9. PubMed ID: 849385
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Measurement of gliclazide in plasma by radial compression reversed-phase liquid chromatography.
    Charles BG; Ravenscroft PJ
    Clin Chem; 1984 Nov; 30(11):1789-91. PubMed ID: 6488522
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of gliclazide on platelet-activating factor-induced platelet aggregation in patients with non-insulin-dependent diabetes mellitus.
    Phenekos C; Siafaka-Kapadai A; Trapali M; Botitsi E; Mavris M
    Metabolism; 1992 May; 41(5 Suppl 1):30-2. PubMed ID: 1574012
    [No Abstract]   [Full Text] [Related]  

  • 68. Studies on fibrin network structure in human plasma. Part II--Clinical application: diabetes and antidiabetic drugs.
    Nair CH; Azhar A; Wilson JD; Dhall DP
    Thromb Res; 1991 Nov; 64(4):477-85. PubMed ID: 1788832
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The "in vitro" effect of gliclazide, a new hypoglycemic agent, on normal human blood platelets].
    Vainer H; Verry M
    Thromb Res; 1974 Apr; 4(4):523-38. PubMed ID: 4215174
    [No Abstract]   [Full Text] [Related]  

  • 70. The gliclazide poster world in Lisbon, 1989.
    Krall LP
    Am J Med; 1991 Jun; 90(6A):87S-88S. PubMed ID: 1908184
    [No Abstract]   [Full Text] [Related]  

  • 71. Reversed-phase high-performance liquid chromatographic determination of gliclazide in human plasma.
    Kimura M; Kobayashi K; Hata M; Matsuoka A; Kaneko S; Kitamura H; Kimura Y
    Chem Pharm Bull (Tokyo); 1980 Jan; 28(1):344-6. PubMed ID: 7363377
    [No Abstract]   [Full Text] [Related]  

  • 72. Effect of high-fibre diet on haemostatic variables in diabetes.
    Simpson HC; Mann JI; Chakrabarti R; Imeson JD; Stirling Y; Tozer M; Woolf L; Meade TW
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1608. PubMed ID: 6282381
    [No Abstract]   [Full Text] [Related]  

  • 73. Metabolic approach to atherosclerosis: effect of gliclazide.
    Brindley DN
    Metabolism; 1992 May; 41(5 Suppl 1):20-4. PubMed ID: 1574010
    [No Abstract]   [Full Text] [Related]  

  • 74. Correlative study of blood coagulation and serum lipids in diabetics without clinically recognizable complications.
    Ghanem MH; Tawfik S; Guirgis FK; el-Sawy M
    Atherosclerosis; 1971; 14(2):277-81. PubMed ID: 5118617
    [No Abstract]   [Full Text] [Related]  

  • 75. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
    Leibowitz G; Cerasi E
    Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
    Palmer KJ; Brogden RN
    Drugs; 1993 Jul; 46(1):92-125. PubMed ID: 7691511
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Oral hypoglycaemic agents.
    Peden N; Newton RW; Feely J
    Br Med J (Clin Res Ed); 1983 May; 286(6377):1564-7. PubMed ID: 6405890
    [No Abstract]   [Full Text] [Related]  

  • 78. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
    Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Adverse cardiovascular effects of sulphonylurea drugs. Clinical significance.
    Huupponen R
    Med Toxicol; 1987; 2(3):190-209. PubMed ID: 3298923
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of type II diabetes.
    Nattrass M
    Br Med J (Clin Res Ed); 1986 Apr; 292(6527):1033-4. PubMed ID: 3083989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.